| Literature DB >> 24490070 |
Erik Johnsen1, Kristina Aanesen2, Sanjeevan Sriskandarajah3, Rune A Kroken2, Else-Marie Løberg4, Hugo A Jørgensen5.
Abstract
QTc interval prolongation is a side effect of several antipsychotic drugs, with associated risks of torsade de pointes arrhythmias and sudden cardiac death. There is an ongoing debate of whether or not electrocardiogram (ECG) assessments should be mandatory in patients starting antipsychotic drugs. To investigate QTc prolongation in a clinically relevant patient group 171 adult patients acutely admitted to an emergency ward for psychosis were consecutively recruited. ECGs were recorded at baseline and then at discharge or after 6 weeks at the latest (discharge/6 weeks), thus reflecting the acute phase treatment period. The mean QTc interval was 421.1 (30.4) ms at baseline and there was a positive association between the QTc interval and the agitation score whereas the QTc interval was inversely associated with the serum calcium level. A total of 11.6% had abnormally prolonged QTc intervals and another 14.3% had borderline prolongation. At discharge/6 weeks, the corresponding proportions were reduced to 4.2% and 5.3%, respectively. The reduction of the proportion with prolonged QTc intervals reached statistical significance (chi-square exact test: P = 0.046). The finding of about one-quarter of the patients with borderline or prolonged QTc intervals could indicate mandatory ECG recordings in this population. This trial is registered with ClinicalTrials.gov ID: NCT00932529.Entities:
Year: 2013 PMID: 24490070 PMCID: PMC3893875 DOI: 10.1155/2013/375020
Source DB: PubMed Journal: Schizophr Res Treatment ISSN: 2090-2093
Baseline demographics and clinical characteristics.
| Characteristics |
| % of sample |
|---|---|---|
| Gender | ||
| Male | 118 | 69.0 |
| Female | 53 | 31.0 |
| Antipsychotic drug naïve | 73 | 42.7 |
| Alcohol use last 6 months | ||
| None | 33 | 19.3 |
| Misuse | 12 | 7.0 |
| Illicit drug use last 6 months | ||
| None | 118 | 69.0 |
| Misuse | 29 | 17.0 |
| Diagnosis1 | ||
| Schz and related | 95 | 57.5 |
| Acute | 13 | 7.9 |
| Drug-induced | 21 | 12.7 |
| Affective | 19 | 11.5 |
| Rest | 17 | 10.2 |
|
| ||
| Mean | SD/range | |
|
| ||
| Age | 34.2 | 13.9/17–73 |
| PANSS total | 73.5 | 13.7/44–111 |
| PANSS positive | 19.7 | 4.4/11–32 |
| PANSS negative | 19.2 | 7.5/7–39 |
| PANSS general | 34.6 | 6.8/20–56 |
| CDSS | 6.9 | 5.3/0–23 |
| GAF-F | 30.9 | 6.0/10–62 |
| CGI | 5.2 | 0.6/4–6 |
| RBANS, | 38.3 | 7.5/20–58 |
Notes. N = number of patients with ECG at baseline and/or ECG at discharge; SD = standard deviation; antipsychotic drug naive = no life-time exposure to antipsychotic drugs before index admission; first admission = index admission was the first admission to a mental hospital; misuse = misuse or dependence according to the Clinical Drug and Alcohol Use Scales (CDUS/CAUS); patients with no illicit drug use could be included in the category alcohol use last 6 months; Schz and related = schizophrenia and related disorders: schizophrenia, schizoaffective disorder, acute polymorphic psychotic disorder with symptoms of schizophrenia, acute schizophrenia-like psychotic disorder, and delusional disorder; acute = acute psychosis other than those categorized under Schz and related; affective = affective psychosis; rest = miscellaneous psychotic disorders. All diagnoses are according to ICD-10; PANSS = the positive and negative syndrome scale; CDSS = the Calgary Depression Scale for Schizophrenia; GAF-F = the Global Assessment of Functioning—Split Version, Functions scale; CGI = the Clinical Global Impression, Severity of Illness scale; RBANS = the repeatable battery for the assessment of neuropsychological status.
1Patients with missing diagnoses are not included in the list.
Figure 1Distribution of QTc intervals at baseline.
Figure 2Distribution of QTc intervals at discharge/6 weeks.
Antipsychotic drug use and QTc intervals at discharge/6 weeks.
| Risperidone | Olanzapine | Quetiapine | Ziprasidone | Aripiprazole | |
|---|---|---|---|---|---|
| Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | |
| Mean dose (mg/d) | 3.5 (1.2) | 16.4 (5.9) | 457.4 (222.2) | 86.7 (39.0) | 5.0 (—) |
| Serum level (nm/L)* | 71.6 (47.9) | 121.6 (77.7) | 501.9 (555.1) | 125.3 (99.8) | 141 (—) |
| QTc (ms) | 411.3 (24.6) | 411.6 (27.0) | 412.6 (16.4) | 412.5 (19.9) | 362.0 (—) |
Notes. N = number of patients; SD = standard deviation; mg/d = milligrams per day; nm/L = nanomoles per litre; ms = milliseconds.
*Reference ranges: risperidone 30–120; olanzapine 30–200; quetiapine 100–800; ziprasidone 30–200; aripiprazole 200–1300.